Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
The Eating Disorder Examination Questionnaire: Reliability and validity of the Italian version
Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC
The success of GLP-1 therapies has driven: Increased research investments Expansion of manufacturing capacity Development of new formulations Greater focus on metabolic disease management India is now emerging as an important market for these innovative therapies
Roughly 95% of the fibrotic MASH group met a conventional indication, primarily due to weight-related conditions
US$ 23.16
US$ 21.88
US$ 27.48
US$ 22.12
US$ 28.42
US$ 29.30
US$ 25.34
